Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
20%(1 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_1
4
67%
Ph phase_2
2
33%

Phase Distribution

4

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
4(66.7%)
Phase 2Efficacy & side effects
2(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(5)
Terminated(1)

Detailed Status

Completed5
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
83.3%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (66.7%)
Phase 22 (33.3%)

Trials by Status

completed583%
terminated117%

Recent Activity

0 active trials
Showing 5 of 6
terminatedphase_2

Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD)

NCT04465916
completedphase_2

A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir

NCT04365933
completedphase_1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EYP001a in Healthy Volunteers and Nonalcoholic Steatohepatitis Patients

NCT03976687
completedphase_1

Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects

NCT03272009
completedphase_1

EYP001a Food Effect Study in Subjects With Chronic Hepatitis B Virus (HBV) Infection

NCT03320616
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04465916Phase 2

Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD)

Terminated
NCT04365933Phase 2

A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir

Completed
NCT03976687Phase 1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EYP001a in Healthy Volunteers and Nonalcoholic Steatohepatitis Patients

Completed
NCT03272009Phase 1

Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects

Completed
NCT03320616Phase 1

EYP001a Food Effect Study in Subjects With Chronic Hepatitis B Virus (HBV) Infection

Completed
NCT03110276Phase 1

Study Evaluating Safety, Tolerability and Pharmacokinetics of EYP001a in Healthy Male Subjects

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6